Legal & General Group
ANIP icon

Legal & General Group’s ANI Pharmaceuticals ANIP Stock Holding History

Legal & General Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73M Buy
45,075
+5,109
+13% +$410K ﹤0.01% 1712
2026
Q1 		$3.07M Sell
39,966
-4,314
-10% -$337K ﹤0.01% 1734
2025
Q4 		$3.5M Buy
44,280
+164
+0.4% +$14.2K ﹤0.01% 1757
2025
Q3 		$4.04M Sell
44,116
-2,596
-6% -$212K ﹤0.01% 1686
2025
Q2 		$3.05M Buy
46,712
+351
+0.8% +$22.9K ﹤0.01% 1791
2025
Q1 		$3.1M Sell
46,361
-2,064
-4% -$123K ﹤0.01% 1745
2024
Q4 		$2.68M Buy
48,425
+3,704
+8% +$213K ﹤0.01% 1857
2024
Q3 		$2.67M Buy
44,721
+1,727
+4% +$105K ﹤0.01% 1852
2024
Q2 		$2.74M Buy
42,994
+1,139
+3% +$73.9K ﹤0.01% 1802
2024
Q1 		$2.89M Buy
41,855
+200
+0.5% +$12.1K ﹤0.01% 1772
2023
Q4 		$2.3M Sell
41,655
-2,195
-5% -$121K ﹤0.01% 1878
2023
Q3 		$2.55M Buy
43,850
+5,646
+15% +$326K ﹤0.01% 1791
2023
Q2 		$2.06M Buy
38,204
+8,882
+30% +$394K ﹤0.01% 1917
2023
Q1 		$1.16M Sell
29,322
-426
-1% -$18K ﹤0.01% 2099
2022
Q4 		$1.2M Buy
29,748
+1,021
+4% +$38.3K ﹤0.01% 2101
2022
Q3 		$923K Sell
28,727
-1,521
-5% -$52.1K ﹤0.01% 2167
2022
Q2 		$897K Buy
30,248
+802
+3% +$23.1K ﹤0.01% 2198
2022
Q1 		$828K Buy
29,446
+3,106
+12% +$116K ﹤0.01% 2277
2021
Q4 		$1.21M Buy
26,340
+4,376
+20% +$188K ﹤0.01% 2194
2021
Q3 		$721K Buy
21,964
+1,496
+7% +$46.5K ﹤0.01% 2328
2021
Q2 		$716K Sell
20,468
-6,141
-23% -$209K ﹤0.01% 2270
2021
Q1 		$963K Buy
26,609
+284
+1% +$8.89K ﹤0.01% 2204
2020
Q4 		$764K Sell
26,325
-134
-0.5% -$3.84K ﹤0.01% 2177
2020
Q3 		$746K Buy
26,459
+673
+3% +$20K ﹤0.01% 2105
2020
Q2 		$834K Buy
25,786
+2,177
+9% +$78.1K ﹤0.01% 2036
2020
Q1 		$961K Sell
23,609
-36
-0.2% -$1.92K ﹤0.01% 1861
2019
Q4 		$1.46M Buy
23,645
+1,790
+8% +$119K ﹤0.01% 1931
2019
Q3 		$1.59M Buy
21,855
+1,972
+10% +$148K ﹤0.01% 1817
2019
Q2 		$1.63M Buy
19,883
+334
+2% +$23.8K ﹤0.01% 1787
2019
Q1 		$1.38M Buy
19,549
+1,984
+11% +$117K ﹤0.01% 1853
2018
Q4 		$784K Sell
17,565
-147
-0.8% -$7.7K ﹤0.01% 1982
2018
Q3 		$998K Sell
17,712
-164
-0.9% -$10K ﹤0.01% 1958
2018
Q2 		$1.2M Buy
17,876
+1,318
+8% +$82.3K ﹤0.01% 1872
2018
Q1 		$963K Buy
16,558
+417
+3% +$26.5K ﹤0.01% 1899
2017
Q4 		$1.04M Hold
16,141
– – ﹤0.01% 1871
2017
Q3 		$847K Buy
16,141
+1,560
+11% +$74.4K ﹤0.01% 1934
2017
Q2 		$683K Buy
14,581
+1,618
+12% +$78.1K ﹤0.01% 1961
2017
Q1 		$642K Sell
12,963
-33
-0.3% -$1.85K ﹤0.01% 1951
2016
Q4 		$788K Buy
12,996
+6,394
+97% +$391K ﹤0.01% 1837
2016
Q3 		$438K Buy
6,602
+5,513
+506% +$345K ﹤0.01% 1755
2016
Q2 		$61K Hold
1,089
– – ﹤0.01% 2359
2016
Q1 		$36K Hold
1,089
– – ﹤0.01% 2541
2015
Q4 		$51K Hold
1,089
– – ﹤0.01% 2449
2015
Q3 		$41K Hold
1,089
– – ﹤0.01% 2544
2015
Q2 		$67K Hold
1,089
– – ﹤0.01% 2402
2015
Q1 		$68K Buy
1,089
+803
+281% +$48.8K ﹤0.01% 2306
2014
Q4 		$16K Buy
+286
New +$12.6K ﹤0.01% 2643

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Legal & General Group's ANIP Position: Q2 2026 in Review

Legal & General Group increased its ANI Pharmaceuticals (ANIP) stake by 13% in Q2 2026, buying an estimated $410K and bringing the position to 45,075 shares worth $3.73M. The position accounts for ﹤0.01% of the portfolio, ranked #1712.

Legal & General Group first reported a position in ANIP in Q4 2014 and has held it in 47 quarters since. The position peaked at $4.04M in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • Legal & General Group held 45,075 shares of ANI Pharmaceuticals worth $3.73M as of Q2 2026.
  • Legal & General Group bought 5,109 ANI Pharmaceuticals shares in Q2 2026, an estimated $410K.
  • ANI Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1712 holding.
  • Legal & General Group first reported a position in ANI Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
  • Legal & General Group's ANI Pharmaceuticals position peaked at $4.04M in Q3 2025.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.